NeuroSense Therapeutics Announces Positive 18-Month Data from Phase 2b PARADIGM Study of PrimeC in ALS
Reuters
Sep 02, 2025
NeuroSense <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive 18-Month Data from Phase 2b PARADIGM Study of PrimeC in ALS
NeuroSense Therapeutics Ltd. has announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in patients with Amyotrophic Lateral Sclerosis (ALS). The analysis revealed a statistically significant effect at 18 months, with a p-value of 0.03, as demonstrated by the NfL-adjusted MMRM analysis. Participants who received PrimeC from the onset of the study exhibited a 28% relative difference in the decline of the ALS Functional Rating Scale-Revised compared to those who started with a placebo and were administered PrimeC after six months. The data suggests the clinical importance of early initiation of PrimeC in disease progression. The results were adjusted for baseline neurofilament light levels, confirming consistent benefits after considering patient variability. This report indicates PrimeC's potential as a disease-modifying therapy for ALS, though it does not specify if or when these results will be presented at future events.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-082945), on September 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.